<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658462</url>
  </required_header>
  <id_info>
    <org_study_id>VAROCE - 1206</org_study_id>
    <secondary_id>2012-002214-38</secondary_id>
    <nct_id>NCT01658462</nct_id>
  </id_info>
  <brief_title>Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer</brief_title>
  <acronym>VAROCE-1206</acronym>
  <official_title>A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      National, randomized, unblinded, phase IIb trial with 2 strata: First-line chemotherapy /&#xD;
      Second-line chemotherapy for locally recurrent or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be stratified at randomization according to first-line chemotherapy /&#xD;
      Second-line chemotherapy for metastatic or locally recurrent breast cancer&#xD;
&#xD;
      Treatment until progression or unacceptable toxicity Visits are planned every 3 weeks during&#xD;
      treatment and every 3 months after end of treatment or patient's withdrawal&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) in patients receiving Docetaxel + Nintedanib treatment (Arm A) compared to Docetaxel alone (Arm B)</measure>
    <time_frame>baseline, every 9 weeks (or 3 cycles), up to 6 months</time_frame>
    <description>6-months progression free disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>baseline, every 9 weeks (or 3 cycles), up to 6 months</time_frame>
    <description>according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>time from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life by QLQ-C30 and additionnel module BR23</measure>
    <time_frame>baseline, every 9 weeks (or 3 cycles), up to 6 months</time_frame>
    <description>questionnaire : EORTC QLQ C30 (Additional module BR23)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological markers levels in tumors and endothelial cells</measure>
    <time_frame>baseline, every 9 weeks (or 3 cycles), up to 6 months</time_frame>
    <description>biological analysis of cells RT-qPCR analysis, including endothelial cells using a specific reference gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological markers in patient serum</measure>
    <time_frame>baseline, every 9 weeks (or 3 cycles), up to 6 months</time_frame>
    <description>biological analysis in patient's serum Dosage of VEGF-A, -C, FGF-1, -2, PDGF-AA, -AB, -BB in patient's serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile of Nintedanib</measure>
    <time_frame>before each cycle, 3 weeks after the last dose or at the end of study</time_frame>
    <description>according to NCI CTCAE v3.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel + Nintedanib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel + increase of the dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 IV Day 1 / 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>200 mg x 2 per os daily from D2*&#xD;
*No Nintedanib on days when docetaxel is administered</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>OFEV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel: increase of the dose</intervention_name>
    <description>Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
          -  Locally recurrent or metastatic disease&#xD;
&#xD;
          -  HER 2 negative status&#xD;
&#xD;
          -  Requiring a first or a second-line chemotherapy for locally recurrent or metastatic&#xD;
             disease.&#xD;
&#xD;
          -  Prior first line chemotherapy not containing Docetaxel&#xD;
&#xD;
          -  Measurable or evaluable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Allowed prior chemotherapy as follows :&#xD;
&#xD;
               -  Docetaxel in the neoadjuvant or adjuvant setting is allowed provided that relapse&#xD;
                  has been observed more than 12 months after the end of docetaxel treatment&#xD;
&#xD;
               -  Bevacizumab in 1st line is allowed with a wash-out of 4 weeks, with recovery to&#xD;
                  NCI-CTCAE v3.0 toxicity&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal functions as evidence by the following:&#xD;
&#xD;
               -  Hemoglobin ≥ 10 G/100 mL&#xD;
&#xD;
               -  Neutrophils count ≥ 1500 /mm3&#xD;
&#xD;
               -  Platelets ≥ 100 000 /mm3&#xD;
&#xD;
               -  Total bilirubin ≤ ULN (ULN:Upper Limit of Normal)&#xD;
&#xD;
               -  SGOT/SGPT ≤ 1.5 x ULN (≤ 2.5 x ULN in case of hepatic metastasis)&#xD;
&#xD;
               -  Serum alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
               -  Creatinin clearance ≥ 45 ml/min or creatinin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Proteinuria &lt; CTCAE grade 2&#xD;
&#xD;
          -  Coagulation parameters: International normalised ratio (INR) ≤ 2, prothrombin time&#xD;
             (PT) and partial thromboplastin time (PTT) ≤ 50% of deviation of institutional ULN&#xD;
&#xD;
          -  Effective contraception for patients (male and female) with reproductive potential&#xD;
             during their entire participation in the study and during 3 months after the last&#xD;
             administration of Nintedanib or Docetaxel&#xD;
&#xD;
          -  Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of&#xD;
             study treatment in females with reproductive potential&#xD;
&#xD;
          -  Patient covered by government health insurance&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with ICH-GCP guidelines and to the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant hormone therapy for metastatic breast cancer&#xD;
&#xD;
          -  Patients with dysphagia, or inability to swallow the tablets&#xD;
&#xD;
          -  Other serious illness or medical conditions: Cardiac disease&#xD;
&#xD;
          -  Unstable diabetes&#xD;
&#xD;
          -  Uncontrolled hypercalcemia&#xD;
&#xD;
          -  Pregnancy or breast feeding woman&#xD;
&#xD;
          -  Unable for medical follow-up (geographic, social or mental reasons)&#xD;
&#xD;
          -  Prior treatment with Nintedanib or any other VEGFR inhibitor&#xD;
&#xD;
          -  Known hypersensitivity to the trial drugs , to their excipients, to peanut, to soya or&#xD;
             to contrast media&#xD;
&#xD;
          -  Contra indication to the use of the backbone treatment and to the comparator&#xD;
&#xD;
          -  Active brain metastases (e.g. stable for &lt;4 weeks, no adequate previous treatment with&#xD;
             radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone&#xD;
             therapy will be allowed if administered as stable dose for at least one month before&#xD;
             randomisation)&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  Radiographic evidence of cavitary or necrotic tumors&#xD;
&#xD;
          -  Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of&#xD;
             major blood vessels&#xD;
&#xD;
          -  History of clinically significant haemorrhagic or thromboembolic event in the past 6&#xD;
             months&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or thrombosis&#xD;
&#xD;
          -  Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina,&#xD;
             history of infarction within the past 12 months prior to start of study treatment,&#xD;
             congestive heart failure &gt; NYHA II, serious cardiac arrhythmia, pericardial effusion)&#xD;
&#xD;
          -  Other malignancies within the past 5 years other than basal cell skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  Active serious infections in particular if requiring systemic antibiotic or&#xD;
             antimicrobial therapy&#xD;
&#xD;
          -  Active or chronic hepatitis C and/or B infection&#xD;
&#xD;
          -  Active alcohol or drug abuse&#xD;
&#xD;
          -  Significant weight loss (&gt; 10% of BW) within past 6 months prior to inclusion into the&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques BONNETERRE, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Oscar Lambret Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens- Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80 054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé les Bonnettes</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Pierre Curie</name>
      <address>
        <city>Beuvry</city>
        <zip>62660</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Compiègne-Noyon</name>
      <address>
        <city>Compiègne</city>
        <zip>60200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léonard de Vinci</name>
      <address>
        <city>Dechy</city>
        <zip>59 187</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59 020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Limoges - site Chénieux</name>
      <address>
        <city>Limoges</city>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMCO de la Côte d'Opale</name>
      <address>
        <city>Saint-Martin-Boulogne</city>
        <zip>62280</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvelle Clinique des Dentellières</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54 500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally recurrent or metastatic breast cancer</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Nintedanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

